RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:251589

Astrocytoma grade 3

high confidenceDisorder

Also known as: Anaplastic astrocytoma

Publications

14,811

98.2th percentile

Trials

190

Interventional, condition-specific

Researchers

1,367

Distinct authors in sample

Gene link

BRAF

Limited

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, high-grade, malignant glial tumor, histologically characterized by abundance of pleomorphic astrocytes and multiple mitotic figures, often associated with diffuse infiltration of the surrounding tissue, considerable edema and mass effect and involvement of the contralateral brain. Depending on the primary localization of the tumor, patients can present with signs of raised intracranial pressure (headache, vomiting, papilledema), , neurological deficits, and/or behavioral changes. The tumor is most commonly localized in the frontal and temporal lobes, brain stem and spinal cord.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

anaplastic astrocytoma · astrocytoma, anaplastic, malignant · grade III astrocytic neoplasm · grade III astrocytic tumor · grade III astrocytic tumour · grade III astrocytoma · malignant astrocytoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Limited — BRAF

  2. LiteraturePresent

    14,811 matched papers (7,643 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    190 matched on ClinicalTrials.gov (15 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Possibly — only limited evidence so far for BRAF.

GenCC classification: Limited.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

14,811

14,811 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

14,811 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

7,643 in the last 10 years · high confidence · 98.2th percentile (publications denominator)

Phrase hits: 14,811 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,367

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y6 papers · 2026

    Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

    Papers in Europe PMC
  2. 02
    Li J5 papers · 2026

    Department of Stomatology, The First Affiliated Hospital of Hunan Traditional Chinese Medical College (Hunan Provincial Directly Affiliated Hospital of Traditional Chinese Medicine), Zhuzhou, China.

    Papers in Europe PMC
  3. 03
    Jakubowicz-Gil J4 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.

    Papers in Europe PMC
  4. 04
    Liu Y4 papers · 2025

    Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

    Papers in Europe PMC
  5. 05
    Rzeski W4 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.

    Papers in Europe PMC
  6. 06
    Chen Z3 papers · 2025

    Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, 060-0815, Japan.

    Papers in Europe PMC
  7. 07
    Lu X3 papers · 2024
    Papers in Europe PMC
  8. 08
    Maciejczyk A3 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.

    Papers in Europe PMC
  9. 09
    Sumorek-Wiadro J3 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland. joanna.sumorek-wiadro@mail.umcs.pl.

    Papers in Europe PMC
  10. 10
    Wang F3 papers · 2026

    Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

190

interventional trials for this specific condition

190 interventional trials matched this specific condition name; 15 currently recruiting in our sample.

Data as of 27 July 2026

190 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.2th percentile).

high confidence · 99.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

190 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Astrocytoma grade 3" OR "Anaplastic astrocytoma" OR "astrocytoma, anaplastic, malignant" OR "grade III astrocytic neoplasm" OR "grade III astrocytic tumor" OR "grade III astrocytic tumour" OR "grade III astrocytoma" OR "malignant astrocytoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Astrocytoma grade 3" OR "Anaplastic astrocytoma" OR "astrocytoma, anaplastic, malignant" OR "grade III astrocytic neoplasm" OR "grade III astrocytic tumor" OR "grade III astrocytic tumour" OR "grade III astrocytoma" OR "malignant astrocytoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 190 interventional · 17 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T10:48:19.794Z